Cost Insights: Breaking Down Bio-Techne Corporation and Amphastar Pharmaceuticals, Inc.'s Expenses

Comparing Cost Trends: Bio-Techne vs. Amphastar (2014-2023)

__timestampAmphastar Pharmaceuticals, Inc.Bio-Techne Corporation
Wednesday, January 1, 2014159205000106352000
Thursday, January 1, 2015174172000144969000
Friday, January 1, 2016150976000162364000
Sunday, January 1, 2017149380000188462000
Monday, January 1, 2018187681000210850000
Tuesday, January 1, 2019190434000240515000
Wednesday, January 1, 2020206506000255497000
Friday, January 1, 2021238029000298182000
Saturday, January 1, 2022250127000349103000
Sunday, January 1, 2023293274000366887000
Monday, January 1, 2024389335000
Loading chart...

Unleashing the power of data

Cost Insights: Bio-Techne Corporation vs. Amphastar Pharmaceuticals, Inc.

In the ever-evolving biotech industry, understanding cost structures is crucial for investors and stakeholders. This analysis delves into the annual cost of revenue trends for Bio-Techne Corporation and Amphastar Pharmaceuticals, Inc. from 2014 to 2023. Over this period, Bio-Techne consistently outpaced Amphastar, with a notable 245% increase in cost of revenue, peaking at approximately $389 million in 2023. Amphastar, while showing a steady rise, reached its highest cost of revenue at around $293 million in 2023, marking an 84% increase since 2014. The data highlights Bio-Techne's aggressive growth strategy, reflected in its higher cost base. However, the absence of 2024 data for Amphastar suggests potential volatility or strategic shifts. Investors should consider these trends when evaluating the financial health and strategic direction of these biotech giants.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025